Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa
(RTTNews) - French drug major Sanofi (SNYNF, SNY) and South African biopharmaceutical company Biovac Institute (Pty) Ltd. announced Thursday their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa.
The agreement is designed to enable regional manufacturing of polio vaccines to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer of IPV on and for the African continent.
It also supports the Africa Centers for Disease Control and Prevention's ambition to have 60 percent of local vaccines produced in Africa by 2040.
Sanofi has been a critical partner of the Global Polio Eradication Initiative since 1988 and has supplied the world and UNICEF with more than 1.5 billion doses of IPV through Vaccine Alliance GAVI.
Sanofi will continue to produce the bulk of IPV and Biovac, who will hold the marketing authorization, will be responsible for late-stage formulation, filling, packaging, and delivery of millions of IPV doses to UNICEF for GAVI countries in Africa.
Sanofi, OpenAI To Build AI Software To Boost Drug Development
Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up
Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips
Sanofi Q4 Profit Climbs, Sees Slower Earnings Growth In FY23; Stock Down
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Tech Shares Likely To Weigh On Taiwan Stock Market
South Korea Has $3.17 Billion Trade Surplus
